Health Care/Hospital
China Ping An Insurance Overseas (Holdings) Limited Raised Fund of USD 850 Million for Overseas Private Equity Investing
HONG KONG, Oct. 18, 2024 /PRNewswire/ -- China Ping An Insurance Overseas (Holdings) Limited, the main offshore investment and asset management platform of Ping An Insurance (Group) Company ofChina, Ltd. (2318.HK, 601318.SH), together with its subsidiaries ("PAOH" or "Ping An"), announces the suc...
2024-10-18 15:43
1458
Ping An Health Upgrades Chronic Disease Management Services with Significant Results in Digital Weight Management Program
HONG KONG and SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- The Weight Management and Public Health Action Conference, hosted by the National Center for Chronic and Noncommunicable Disease Control and Prevention ("NCNCD") and its affiliated institution, the Binhai Institute for Chronic Disease Control ...
2024-10-18 12:13
2971
Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library
SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxieyi, he frankly and confidently expressed, "Nine years of ...
2024-10-17 22:00
1214
Ublives Introduces SoleFlux Relax Compression Boots: The Perfect Gift for Parents to Relieve Leg Pain
NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Ublives has officially launched its latest innovation: the SoleFlux Relax Compression Boots. These boots are designed to effectively relieve leg pain and discomfort. They are not only an ideal gift for parents but also a practical solution for anyone suffer...
2024-10-17 22:00
1213
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of t...
2024-10-17 21:38
1661
Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress
SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, taking place f...
2024-10-17 18:39
1001
KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-br...
2024-10-17 15:44
1111
EmeTerm Smart and HeadaTerm 2 Achieve Health Canada MDL Certification
VANCOUVER, BC, Oct. 16, 2024 /PRNewswire/ -- WAT Medical Enterprise proudly announces a significant achievement: both EmeTerm Smart and HeadaTerm 2 have received Medical Device Licences (MDL) from Health Canada. EmeTerm Smart was certified onAugust 12, 2024, followed by HeadaTerm 2 on September 2...
2024-10-16 21:30
1079
Copper-67 SAR-bisPSMA updates
SYDNEY, Oct. 16, 2024 /PRNewswire/ -- HIGHLIGHTS Cohort 4 - SECuRE Trial * The third participant of cohort 4 (multi-dose) of the SECuRE trial1 has now completed the Dose Limiting Toxicity (DLT) period after a second dose of 12GBq of67Cu-SAR-bisPSMA, following on from the announcement dated 1...
2024-10-16 21:03
2260
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards ...
2024-10-16 20:00
3162
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently...
2024-10-16 19:02
1264
TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections
SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than300 million RMB. New investor AMR Action F...
2024-10-16 18:00
1654
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies
PISCATAWAY, N.J., Oct. 16, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...
2024-10-16 17:43
1024
SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA
TOKYO, Oct. 16, 2024 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based inTokyo, Japan, announces that its self-developed next-generation HIFU (High-Intensity Focused Ultrasound) therapy system (development code: Suizenji) has been designated as a breakthrough ...
2024-10-16 14:00
1168
PharmAust affirms corporate strategy with name change to Neurizon Therapeutics
MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to announce it has officially changed its name from PharmAust L...
2024-10-16 04:14
1317
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The abstract of the Phase II clinical study (CGZ203 trial) on...
2024-10-15 22:08
1381
Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis'
- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease - Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical trial data analysis expertise SEOUL, South Korea, Oct. 1...
2024-10-15 21:00
1263
Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation
MILAN, Oct. 15, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, unveiled its Hyatrue® Sterile Sodium Hyaluronate (HA) and showcased its BloomseaN™ Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) at CPHI Milan. Known to be at "the...
2024-10-15 21:00
793
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. * PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney...
2024-10-15 09:51
1261
Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations
VEVEY, Switzerland, Oct. 14, 2024 /PRNewswire/ -- Recently at Nestlé's headquarters inVevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its "Human Milk Oligosaccharides (HMO) Research Traceability Journey". With a focus on the most rece...
2024-10-14 23:31
1156
Week's Top Stories
Most Reposted
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 252 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 244 media titles]
2024-12-25 15:45Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
12177
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
2024-12-20 16:25
7143